BackRapport Therapeutics Overview

Rapport Therapeutics Profit Margin

Latest profit margin for Rapport Therapeutics: -5.36% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-99.28%

As of Mar 2026

Annual Profit Margin (TTM)

-536.38%

Trailing 12 months ending Mar 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading
Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Rapport Therapeutics (RAPP) FAQ

The latest profit margin for RAPP is -5.36% as of March 2026. That is below the sector sector average of 19.69%. Investors often review this figure alongside Rapport Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, RAPP currently prints -5.36% for profit margin, while the sector average sits near 19.69%. That is roughly 2824.0% below the sector mean. Large gaps often invite a closer look at Rapport Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Rapport Therapeutics converts resources into returns. At -5.36%, RAPP may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RAPP's profit margin (-5.36%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.